Therapeutic Area: Oncology

The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy

Li D, et al.
Inflamm Bowel Dis
May 2022
Authors and Affiliates
Dalin Li 1, Alexander Xu 2, Emebet Mengesha 1, Rebecca Elyanow 3, Rachel M Gittelman 3, Heidi Chapman 3, John C Prostko 4, Edwin C Frias 4, James L Stewart 4, Valeriya Pozdnyakova 1, Philip Debbas 1, Angela Mujukian 1, Arash A Horizon 5, Noah Merin 2, Sandy Joung 6, Gregory J Botwin 1, Kimia Sobhani 7, Jane C Figueiredo 2, Susan Cheng 6, Ian M Kaplan 2, Dermot P B McGovern 1, Akil Merchant 2, Gil Y Melmed 1, Jonathan Braun 1,7; 1 *F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 2 Cedars Sinai Cancer and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 3 Adaptive Biotechnologies, Seattle, WA, USA. 4 Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL. 5 Center for Rheumatology Medical Group, Los Angeles, CA, USA. 6 Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 7 Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Neoantigen-specific CD4 + T cells in human melanoma have diverse differentiation states and correlate with CD8 + T cell, macrophage, and B cell function

Veatch JR, et al.
Cancer Cell
May 2022
immuneAccess
Authors and Affiliates
Joshua R Veatch 1, Sylvia M Lee 2, Carolyn Shasha 3, Naina Singhi 3, Julia L Szeto 3, Ata S Moshiri 4, Teresa S Kim 5, Kimberly Smythe 3, Paul Kong 3, Matthew Fitzgibbon 3, Brenda Jesernig 3, Shailender Bhatia 2, Scott S Tykodi 2, Evan T Hall 2, David R Byrd 5, John A Thompson 2, Venu G Pillarisetty 5, Thomas Duhen 6, A McGarry Houghton 3, Evan Newell 3, Raphael Gottardo 3, Stanley R Riddell 3; 1 Department of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: jveatch@fredhutch.org. 2 Department of Medical Oncology, University of Washington, Seattle, WA, USA. 3 Department of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 4 Department of Dermatology, University of Washington, Seattle, WA, USA. 5 Department of Surgery, University of Washington, Seattle, WA, USA. 6 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.

Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8 + T-cell large granular lymphocytic leukemia

Huuhtanen J, et al.
Nature Communications
May 2022
immuneAccess
Authors and Affiliates
Jani Huuhtanen #,1,2,3, Dipabarna Bhattacharya #,1,2, Tapio Lönnberg 4,5, Matti Kankainen 1,2, Cassandra Kerr 6, Jason Theodoropoulos 1,2,3, Hanna Rajala 1,2, Carmelo Gurnari 6, Tiina Kasanen 1,2, Till Braun 7, Antonella Teramo 8,9, Renato Zambello 8,9, Marco Herling 7,10, Fumihiro Ishida 11,12, Toru Kawakami 11,12, Marko Salmi 5,13, Thomas Loughran 14, Jaroslaw P Maciejewski 6, Harri Lähdesmäki 3, Tiina Kelkka 1,2, Satu Mustjoki 15,16,17; 1 Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. 2 Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland. 3 Department of Computer Science, Aalto University, Espoo, Finland. 4Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland. 5 InFlames Flagship Center, University of Turku, Turku, Finland. 6 Translational Hematology and Oncology Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA. 7 Department I of Internal Medicine, Center for Integrated Oncology (CIO), Aachen-Bonn-Cologne-Duesseldorf, University of Cologne (UoC), Cologne, Germany. 8 Department of Medicine (DIMED), Hematology and Clinical Immunology Branch, Padova University School of Medicine, Padova, Italy. 9 Veneto Institute of Molecular Medicine (VIMM), Padova, Italy. 10 Clinic of Hematology and Cellular Therapy, University of Leipzig, Leipzig, Germany. 11 Department of Biomedical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto, Japan. 12 Division of Hematology, Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan. 13 MediCity Research Laboratory and Institute of Biomedicine, University of Turku, Turku, Finland. 14 Division of Hematology/Oncology, Department of Medicine, UVA Cancer Center, University of Virginia, Charlottesville, VA, USA. 15 Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. satu.mustjoki@helsinki.fi. 16 Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland. satu.mustjoki@helsinki.fi. 17 iCAN Digital Precision Medicine Flagship, Helsinki, Finland. satu.mustjoki@helsinki.fi. # Contributed equally.

Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes

Kim JK, et al.
OncoImmunology
May 2022
Authors and Affiliates
Jin K Kim 1, Chin-Tung Chen 1, Ajaratu Keshinro 1, Asama Khan 1, Canan Firat 2, Chad Vanderbilt 2, Neil Segal 3, Zsofia Stadler 3, Jinru Shia 2, Vinod P Balachandran 1,4, Martin R Weiser 1; 1 Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 2 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 3 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 4 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa

Tasi Y, et al.
May 2022
Authors and Affiliates
Yo-Ting Tsai 1, Julius Strauss 1, Nicole J Toney 1, Caroline Jochems 1, David J Venzon 2, James L Gulley 3, Jeffrey Schlom #,4, Renee N Donahue #,1; 1 Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA. 2 Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA. 3 Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA. 4 Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA schlomj@mail.nih.gov. # Contributed equally.

T cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity

Elyanow R, et al.
JCI Insight
May 2022
immuneAccess
Authors and Affiliates
Rebecca Elyanow 1, Thomas M Snyder 1, Sudeb C Dalai 1 2, Rachel M Gittelman 1, Jim Boonyaratanakornkit 3,4, Anna Wald 3,4,5,6, Stacy Selke 6, Mark H Wener 3,6, Chihiro Morishima 6, Alexander L Greninger 6, Michael Gale Jr 7,8,9, Tien-Ying Hsiang 7, Lichen Jing 3, Michael R Holbrook 10, Ian M Kaplan 1, H Jabran Zahid 11, Damon H May 1, Jonathan M Carlson 11, Lance Baldo 1, Thomas Manley 1, Harlan S Robins 1, David M Koelle 3,4,6,9,12; 1 Adaptive Biotechnologies, Seattle, Washington, USA. 2 Stanford University School of Medicine, Stanford, California, USA. 3 Department of Medicine, University of Washington, Seattle, Washington, USA. 4 Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 5 Department of Epidemiology. 6 Department of Laboratory Medicine and Pathology. 7 Department of Immunology. 8 Department of Microbiology, and. 9 Department of Global Health, University of Washington, Seattle, Washington, USA. 10 National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility, Frederick, Maryland, USA. 11 Microsoft Research, Redmond, Washington, USA. 12 Benaroya Research Institute, Seattle, Washington, USA.

Distinct phenotypic states and spatial distribution of CD8 + T cell clonotypes in human brain metastases

Sudmeier LJ, et al.
Cell Reports Medicine
May 2022
Authors and Affiliates
Lisa J Sudmeier 1, Kimberly B Hoang 2, Edjah K Nduom 2, Andreas Wieland 3, Stewart G Neill 4, Matthew J Schniederjan 4, Suresh S Ramalingam 5, Jeffrey J Olson 2, Rafi Ahmed 6, William H Hudson 7; 1 Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA. 2 Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; Department of Neurological Surgery, Emory University School of Medicine, Atlanta, GA, USA. 3 Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA. 4 Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA. 5 Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA. 6 Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: rahmed@emory.edu. 7 Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: william.hudson@emory.edu.

Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy

Shanavas M, et al.
Clinical Translational Immunology
May 2022
Authors and Affiliates
Mohamed Shanavas 1,2, Soi-Cheng Law 1, Mark Hertzberg 3, Rodney J Hicks 4, John F Seymour 5, Zhixiu Li 6, Lilia Merida de Long 1, Karthik Nath 1, Muhammed B Sabdia 1, Jay Gunawardana 1, Maher K Gandhi 1,7, Colm Keane 1,7; 1 Mater Research University of Queensland Brisbane QLD Australia. 2 Department of Haematology Mater Hospital Brisbane QLD Australia. 3 Department of Haematology Prince of Wales Hospital and University of NSW Randwick NSW Australia. 4 Department of Cancer Imaging Peter MacCallum Cancer Centre East Melbourne Melbourne VIC Australia. 5 Department of Haematology Peter MacCallum Cancer Centre Royal Melbourne Hospital & University of Melbourne Parkville VIC Australia. 6 Centre for Genomics and Personalised Health School of Biomedical Sciences, Faculty of Health Translational Research Institute Queensland University of Technology (QUT) Woolloongabba QLD Australia. 7 Department of Haematology Princess Alexandra Hospital Brisbane QLD Australia.

Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma

Chen R, et al.
May 2022
Authors and Affiliates
Runzhe Chen 1,2,3, Jun Li 2,4, Junya Fujimoto 5, Lingzhi Hong 1, Xin Hu 2, Kelly Quek 1,2, Ming Tang 2, Akash Mitra 2, Carmen Behrens 1, Chi-Wan Chow 5, Peixin Jiang 1, Latasha D Little 2, Curtis Gumbs 2, Xingzhi Song 2, Jianhua Zhang 2, Dongfeng Tan 6, John V Heymach 1, Ignacio Wistuba 5, P Andrew Futreal 2, Don L Gibbons 7, Lauren A Byers 8, Jianjun Zhang 9,10, Alexandre Reuben 11; 1 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. 2 Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. 3 Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, 510060, Guangdong, China. 4 Regor Therapeutics, 2445 Main Street, Second Floor, MA, 02142, Cambridge, USA. 5 Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. 6 Department of Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. 7 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. dlgibbon@mdanderson.org. 8 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. lbyers@mdanderson.org. 9 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jzhang20@mdanderson.org. 10 Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jzhang20@mdanderson.org. 11 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. areuben@mdanderson.org.